Circumventing antivector immunity: Potential use of nonhuman adenoviral vectors

Human Gene Therapy

Volumn 25, Issue 4, 2014, Pages 285-300

  Lopez Gordo, Estrella ^a   Podgorski, Iva I ^b   Downes, Nicholas ^c   Alemany, Ramon ^d  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR;

ADAPTIVE IMMUNITY; ADENOVIRUS; BOVINE ADENOVIRUS; CANINE ADENOVIRUS; CHICK EMBRYO LETHAL ORPHAN VIRUS; CIRCUMVENTING ANTIVECTOR IMMUNITY; FOWL ADENOVIRUS C; FOWL ADENOVIRUS D; FOWL ADENOVIRUS E; HUMAN ADENOVIRUS; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; INNATE IMMUNITY; MURINE ADENOVIRUS A; NONHUMAN; OVINE ADENOVIRUS D; PORCINE ADENOVIRUS; REVIEW; VIRAL GENE THERAPY; VIRAL TROPISM; ADENOVIRIDAE; ADENOVIRUS INFECTION; ANIMAL; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; TRANSGENE;

ADAPTIVE IMMUNITY; ADENOVIRIDAE; ADENOVIRIDAE INFECTIONS; ANIMALS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; IMMUNITY; IMMUNITY, INNATE; TRANSGENES;

EID: 84899076595     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2013.228     Document Type: Review

References (225)

1. Abbink, P., Lemckert, A.A., Ewald, B.A., et al. (2007). Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J. Virol. 81, 4654-4663. (Pubitemid 46668663)
2. Abe, S., Okuda, K., Ura, T., et al. (2009). Adenovirus type 5 with modified hexons induces robust transgene-specific immune responses in mice with pre-existing immunity against adenovirus type 5. J. Gene Med. 11, 570-579.
3. Albert, M.L., Sauter, B., and Bhardwaj, N. (1998). Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392, 86-89. (Pubitemid 28150594)
4. Appledorn, D.M., McBride, A., Seregin, S., et al. (2008). Complex interactions with several arms of the complement system dictate innate and humoral immunity to adenoviral vectors. Gene Ther. 15, 1606-1617.
5. Arnberg, N. (2012). Adenovirus receptors: implications for targeting of viral vectors. Trends Pharmacol. Sci. 33, 442-448.
6. Bailey, A., and Mautner, V. (1994). Phylogenetic relationships among adenovirus serotypes. Virology 205, 438-452. (Pubitemid 24371685)
7. Bangari, D.S., and Mittal, S.K. (2004). Porcine adenoviral vectors evade preexisting humoral immunity to adenoviruses and efficiently infect both human and murine cells in culture. Virus Res. 105, 127-136. (Pubitemid 39207935)
8. Bangari, D.S., and Mittal, S.K. (2005). Porcine adenovirus serotype 3 internalization is independent of CAR and alphavbeta3 or alphavbeta5 integrin. Virology 332, 157-166.
9. Bangari, D.S., and Mittal, S.K. (2006). Development of nonhuman adenoviruses as vaccine vectors. Vaccine 24, 849-862. (Pubitemid 43185300)
10. Bangari, D.S., Sharma, A., and Mittal, S.K. (2005a). Bovine adenovirus type 3 internalization is independent of primary receptors of human adenovirus type 5 and porcine adenovirus type 3. Biochem. Biophys. Res. Commun. 331, 1478-1484. (Pubitemid 40692521)
11. Bangari, D.S., Shukla, S., and Mittal, S.K. (2005b). Comparative transduction efficiencies of human and nonhuman adenoviral vectors in human, murine, bovine, and porcine cells in culture. Biochem. Biophys. Res. Commun. 327, 960-966. (Pubitemid 40092842)
12. Barlan, A.U., Danthi, P., and Wiethoff, C.M. (2011a). Lysosomal localization and mechanism of membrane penetration influence nonenveloped virus activation of the NLRP3 inflammasome. Virology 412, 306-314.
13. Barlan, A.U., Griffin, T.M., McGuire, K.A., and Wiethoff, C.M. (2011b). Adenovirus membrane penetration activates the NLRP3 inflammasome. J. Virol. 85, 146-155.
14. Barouch, D.H., Pau, M.G., Custers, J.H., et al. (2004). Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J. Immunol. 172, 6290-6297. (Pubitemid 38621236)
15. Basner-Tschakarjan, E., Gaffal, E., O'Keeffe, M., et al. (2006). Adenovirus efficiently transduces plasmacytoid dendritic cells resulting in TLR9-dependent maturation and IFN-alpha production. J. Gene Med. 8, 1300-1306. (Pubitemid 44782509)
16. Beard, C.W., and Spindler, K.R. (1996). Analysis of early region 3 mutants of mouse adenovirus type 1. J. Virol. 70, 5867-5874. (Pubitemid 26266798)
17. Belousova, N., Mikheeva, G., Xiong, C., et al. (2010). Development of a targeted gene vector platform based on simian adenovirus serotype 24. J. Virol. 84, 10087-10101.
18. Benkö, M., and Harrach, B. (2003). Molecular evolution of adenoviruses. Curr. Top. Microbiol. Immunol. 272, 3-35. (Pubitemid 36503013)
19. Both, G.W. (2004). Ovine atadenovirus: a review of its biology, biosafety profile and application as a gene delivery vector. Immunol. Cell Biol. 82, 189-195. (Pubitemid 38594651)
20. Bradley, R.R., Lynch, D.M., Iampietro, M.J., et al. (2012a). Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection. J. Virol. 86, 625-629.
21. Bradley, R.R., Maxfield, L.F., Lynch, D.M., et al. (2012b). Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions. J. Virol. 86, 1267-1272.
22. Bradshaw, A.C., Coughlan, L., Miller, A.M., et al. (2012). Biodistribution and inflammatory profiles of novel penton and hexon double-mutant serotype 5 adenoviruses. J. Control. Release 164, 394-402.
23. Brouwer, E., Havenga, M.J., Ophorst, O., et al. (2007). Human adenovirus type 35 vector for gene therapy of brain cancer: improved transduction and bypass of pre-existing anti-vector immunity in cancer patients. Cancer Gene Ther. 14, 211-219. (Pubitemid 46106964)
24. Bru, T., Salinas, S., and Kremer, E.J. (2010). An update on canine adenovirus type 2 and its vectors. Viruses 2, 2134-2153.
25. Bruder, J.T., Semenova, E., Chen, P., et al. (2012). Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responses. PLoS One 7, e33920.
26. Calcedo, R., Vandenberghe, L.H., Roy, S., et al. (2009). Host immune responses to chronic adenovirus infections in human and nonhuman primates. J. Virol. 83, 2623-2631.
27. Capone, S., Meola, A., Ercole, B.B., et al. (2006). A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques. J. Virol. 80, 1688-1699. (Pubitemid 43228711)
28. Carlisle, R.C., Di, Y., Cerny, A.M., et al. (2009). Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood 113, 1909-1918.
29. Cauthen, A.N., Brown, C.C., and Spindler, K.R. (1999). In vitro and in vivo characterization of a mouse adenovirus type 1 early region 3 null mutant. J. Virol. 73, 8640-8646. (Pubitemid 29441728)
30. Cerullo, V., Seiler, M.P., Mane, V., et al. (2007). Toll-like receptor 9 triggers an innate immune response to helperdependent adenoviral vectors. Mol. Ther. 15, 378-385. (Pubitemid 46111889)
31. Charles, P.C., Guida, J.D., Brosnan, C.F., and Horwitz, M.S. (1998). Mouse adenovirus type-1 replication is restricted to vascular endothelium in the CNS of susceptible strains of mice. Virology 245, 216-228. (Pubitemid 28394184)
32. Cheng, C., Gall, J.G., Kong, W.P., et al. (2007). Mechanism of ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells. PLoS Pathog. 3, e25.
33. Cherenova, L.V., Logunov, D.Y., Shashkova, E.V., et al. (2004). Recombinant avian adenovirus CELO expressing the human interleukin-2: characterization in vitro, in ovo and in vivo. Virus Res. 100, 257-261. (Pubitemid 38293051)
34. Chillon, M., and Kremer, E.J. (2001). Trafficking and propagation of canine adenovirus vectors lacking a known integrininteracting motif. Hum. Gene Ther. 12, 1815-1823. (Pubitemid 32911646)
35. Cohen, C.J., Xiang, Z.Q., Gao, G.P., et al. (2002). Chimpanzee adenovirus CV-68 adapted as a gene delivery vector interacts with the coxsackievirus and adenovirus receptor. J. Gen. Virol. 83, 151-155. (Pubitemid 34030819)
36. Corredor, J.C., and Nagy, E. (2010a). A region at the left end of the fowl adenovirus 9 genome that is non-essential in vitro has consequences in vivo. J. Gen. Virol. 91, 51-58.
37. Corredor, J.C., and Nagy, E. (2010b). The non-essential left end region of the fowl adenovirus 9 genome is suitable for foreign gene insertion/replacement. Virus Res. 149, 167-174.
38. Coughlan, L., Alba, R., Parker, A.L., et al. (2010). Tropismmodification strategies for targeted gene delivery using adenoviral vectors. Viruses 2, 2290-2355.
39. Coughlan, L., Bradshaw, A.C., Parker, A.L., et al. (2012). Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery. Mol. Ther. 20, 2268-2281.
40. Crawford-Miksza, L., and Schnurr, D.P. (1996). Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues. J. Virol. 70, 1836-1844. (Pubitemid 26062947)
41. Croyle, M.A., Yu, Q.C., and Wilson, J.M. (2000). Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions. Hum. Gene Ther. 11, 1713-1722.
42. Davison, A.J., Benko, M., and Harrach, B. (2003). Genetic content and evolution of adenoviruses. J. Gen. Virol. 84, 2895-2908. (Pubitemid 37336773)
43. De Geest, B., Snoeys, J., Van Linthout, S., et al. (2005). Elimination of innate immune responses and liver inflammation by PEGylation of adenoviral vectors and methylprednisolone. Hum. Gene Ther. 16, 1439-1451. (Pubitemid 41829019)
44. Dehghan, S., Seto, J., Liu, E.B., et al. (2013). Computational analysis of four human adenovirus type 4 genomes reveals molecular evolution through two interspecies recombination events. Virology 443, 197-207.
45. Di Paolo, N.C., Miao, E.A., Iwakura, Y., et al. (2009). Virus binding to a plasma membrane receptor triggers interleukin-1 alpha-mediated proinflammatory macrophage response in vivo. Immunity 31, 110-121.
46. Doszpoly, A., Wellehan, J.F., Childress, A.L., et al. (2013). Partial characterization of a new adenovirus lineage discovered in testudinoid turtles. Infect. Genet. Evol. 17, 106-112.
47. Dudley, R.W., Lu, Y., Gilbert, R., et al. (2004). Sustained improvement of muscle function one year after full-length dystrophin gene transfer into mdx mice by a gutted helperdependent adenoviral vector. Hum. Gene Ther. 15, 145-156. (Pubitemid 38210530)
48. Ehrhardt, A., and Kay, M.A. (2002). A new adenoviral helperdependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo. Blood 99, 3923-3930. (Pubitemid 35332030)
49. Ersching, J., Hernandez, M.I., Cezarotto, F.S., et al. (2010). Neutralizing antibodies to human and simian adenoviruses in humans and New-World monkeys. Virology 407, 1-6.
50. Eto, Y., Yoshioka, Y., Ishida, T., et al. (2010). Optimized PEGylated adenovirus vector reduces the anti-vector humoral immune response against adenovirus and induces a therapeutic effect against metastatic lung cancer. Biol. Pharm. Bull. 33, 1540-1544.
51. Farina, S.F., Gao, G.P., Xiang, Z.Q., et al. (2001). Replicationdefective vector based on a chimpanzee adenovirus. J. Virol. 75, 11603-11613. (Pubitemid 33063252)
52. Fernandes, P., Peixoto, C., Santiago, V.M., et al. (2013a). Bioprocess development for canine adenovirus type 2 vectors. Gene Ther. 20, 353-360.
53. Fernandes, P., Santiago, V.M., Rodrigues, A.F., et al. (2013b). Impact of E1 and Cre on adenovirus vector amplification: developing MDCK CAV-2-E1 and E1-Cre transcomplementing cell lines. PLoS One 8, e60342.
54. François, A., Eterradossi, N., Delmas, B., et al. (2001). Construction of avian adenovirus CELO recombinants in cosmids. J. Virol. 75, 5288-5301. (Pubitemid 32448551)
55. Gall, J., Kass-Eisler, A., Leinwand, L., and Falck-Pedersen, E. (1996). Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes. J. Virol. 70, 2116-2123. (Pubitemid 26087569)
56. Gall, J.G., Crystal, R.G., and Falck-Pedersen, E. (1998). Construction and characterization of hexon-chimeric adenoviruses: specification of adenovirus serotype. J. Virol. 72, 10260-10264. (Pubitemid 28520902)
57. Gao, W., Robbins, P.D., and Gambotto, A. (2003). Human adenovirus type 35: nucleotide sequence and vector development. Gene Ther. 10, 1941-1949. (Pubitemid 37337070)
58. Garnett, C.T., Erdman, D., Xu, W., and Gooding, L.R. (2002). Prevalence and quantitation of species C adenovirus DNA in human mucosal lymphocytes. J. Virol. 76, 10608-10616. (Pubitemid 35176177)
59. Gattoni, A., Parlato, A., Vangieri, B., et al. (2006). Interferongamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts). Clin. Ther. 157, 377-386. (Pubitemid 44922316)
60. Geisbert, T.W., Bailey, M., Hensley, L., et al. (2011). Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J. Virol. 85, 4222-4233.
61. Ginsberg, H.S. (1996). The ups and downs of adenovirus vectors. Bull. NY Acad. Med. 73, 53-58. (Pubitemid 126815160)
62. Greber, U.F. (2002). Signalling in viral entry. Cell. Mol. Life Sci. 59, 608-626. (Pubitemid 34457539)
63. Green, N.K., Herbert, C.W., Hale, S.J., et al. (2004). Extended plasma circulation time and decreased toxicity of polymercoated adenovirus. Gene Ther. 11, 1256-1263. (Pubitemid 39173432)
64. Greenall, S.A., Tyack, S.G., Johnson, M.A., and Sapats, S.I. (2010). Antibody fragments, expressed by a fowl adenovirus vector, are able to neutralize infectious bursal disease virus. Avian Pathol. 39, 339-348.
65. Haisma, H.J., Boesjes, M., Beerens, A.M., et al. (2009). Scavenger receptor A: a new route for adenovirus 5. Mol. Pharm. 6, 366-374.
66. Hammond, J.M., and Johnson, M.A. (2005). Porcine adenovirus as a delivery system for swine vaccines and immunotherapeutics. Vet. J. 169, 17-27. (Pubitemid 40197654)
67. Havenga, M.J., Lemckert, A.A., Grimbergen, J.M., et al. (2001). Improved adenovirus vectors for infection of cardiovascular tissues. J. Virol. 75, 3335-3342. (Pubitemid 32225896)
68. Haviv, Y.S., Blackwell, J.L., Kanerva, A., et al. (2002). Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. Cancer Res. 62, 4273-4281. (Pubitemid 34827282)
69. Hofherr, S.E., Shashkova, E.V., Weaver, E.A., et al. (2008). Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression. Mol. Ther. 16, 1276-1282. (Pubitemid 351866059)
70. Hofmann, C., Löser, P., Cichon, G., et al. (1999). Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo. J. Virol. 73, 6930-6936. (Pubitemid 29327876)
71. Holterman, L., Vogels, R., van der Vlugt, R., et al. (2004). Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5. J. Virol. 78, 13207-13215. (Pubitemid 39507827)
72. Ibanes, S., and Kremer, E.J. (2013). Canine adenovirus type 2 vector generation via I-Sce1-mediated intracellular genome release. PLoS One 8, e71032.
73. Jankovic, D., Liu, Z., and Gause, W.C. (2001). Th1-and Th2-cell commitment during infectious disease: asymmetry in divergent pathways. Trends Immunol. 22, 450-457. (Pubitemid 32709980)
74. Jian, L., Zhao, Q., Zhang, S., et al. (2013). The prevalence of neutralising antibodies to chimpanzee adenovirus type 6 and type 7 in healthy adult volunteers, patients with chronic hepatitis B and patients with primary hepatocellular carcinoma in China. Arch. Virol. DOI 10.1007/s00705-013-1828-y. [Epub ahead of print]
75. Jones, M.S., Harrach, B., Ganac, R.D., et al. (2007). New adenovirus species found in a patient presenting with gastroenteritis. J. Virol. 81, 5978-5984. (Pubitemid 46847034)
76. Kajon, A.E., Brown, C.C., and Spindler, K.R. (1998). Distribution of mouse adenovirus type 1 in intraperitoneally and intranasally infected adult outbred mice. J. Virol. 72, 1219-1223. (Pubitemid 28116906)
77. Kanerva, A., Mikheeva, G.V., Krasnykh, V., et al. (2002). Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin. Cancer Res. 8, 275-280. (Pubitemid 34101488)
78. Kass-Eisler, A., Leinwand, L., Gall, J., et al. (1996). Circumventing the immune response to adenovirus-mediated gene therapy. Gene Ther. 3, 154-162.
79. Katze, M.G., He, Y., and Gale, M. (2002). Viruses and interferon: a fight for supremacy. Nat. Rev. Immunol. 2, 675-687. (Pubitemid 37328725)
80. Khare, R., Reddy, V.S., Nemerow, G.R., and Barry, M.A. (2012). Identification of adenovirus serotype 5 hexon regions that interact with scavenger receptors. J. Virol. 86, 2293-2301.
81. Khatri, A., Xu, Z.Z., and Both, G.W. (1997). Gene expression by atypical recombinant ovine adenovirus vectors during abortive infection of human and animal cells in vitro. Virology 239, 226-237. (Pubitemid 28027086)
82. Klonjkowski, B., Gilardi-Hebenstreit, P., Hadchouel, J., et al. (1997). A recombinant E1-deleted canine adenoviral vector capable of transduction and expression of a transgene in human-derived cells and in vivo. Hum. Gene Ther. 8, 2103-2115. (Pubitemid 28072580)
83. Kochanek, S., Clemens, P.R., Mitani, K., et al. (1996). A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc. Natl. Acad. Sci. USA 93, 5731-5736.
84. Kremer, E.J., Boutin, S., Chillon, M., and Danos, O. (2000). Canine adenovirus vectors: an alternative for adenovirusmediated gene transfer. J. Virol. 74, 505-512. (Pubitemid 30002932)
85. Kümin, D., Hofmann, C., Rudolph, M., et al. (2002). Biology of ovine adenovirus infection of nonpermissive cells. J. Virol. 76, 10882-10893. (Pubitemid 35176205)
86. Kuriyama, S., Tominaga, K., Kikukawa, M., et al. (1998). Inhibitory effects of human sera on adenovirus-mediated gene transfer into rat liver. Anticancer Res. 18, 2345-2351. (Pubitemid 28386518)
87. Lau, A.A., Rozaklis, T., Ibanes, S., et al. (2012). Helperdependent canine adenovirus vector-mediated transgene expression in a neurodegenerative lysosomal storage disorder. Gene 491, 53-57.
88. Laver, W.G., Younghusband, H.B., and Wrigley, N.G. (1971). Purification and properties of chick embryo lethal orphan virus (an avian adenovirus). Virology 45, 598-614.
89. Leen, A.M., Sili, U., Vanin, E.F., et al. (2004). Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8 + T cells. Blood 104, 2432-2440. (Pubitemid 39331844)
90. Lemckert, A.A., Grimbergen, J., Smits, S., et al. (2006). Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity. J. Gen. Virol. 87, 2891-2899. (Pubitemid 44463897)
91. Lenaerts, L., Verbeken, E., De Clercq, E., and Naesens, L. (2005). Mouse adenovirus type 1 infection in SCID mice: an experimental model for antiviral therapy of systemic adenovirus infections. Antimicrob. Agents Chemother. 49, 4689-4699. (Pubitemid 41552601)
92. Lenaerts, L., Daelemans, D., Geukens, N., et al. (2006). Mouse adenovirus type 1 attachment is not mediated by the coxsackieadenovirus receptor. FEBS Lett. 580, 3937-3942. (Pubitemid 43946887)
93. Lenaerts, L., McVey, J.H., Baker, A.H., et al. (2009). Mouse adenovirus type 1 and human adenovirus type 5 differ in endothelial cell tropism and liver targeting. J. Gene. Med. 11, 119-127.
94. Lenaerts, L., van Dam, W., Persoons, L., and Naesens, L. (2012). Interaction between mouse adenovirus type 1 and cell surface heparan sulfate proteoglycans. PLoS One 7, e31454.
95. Li, X., Bangari, D.S., Sharma, A., and Mittal, S.K. (2009). Bovine adenovirus serotype 3 utilizes sialic acid as a cellular receptor for virus entry. Virology 392, 162-168.
96. Liu, Q., White, L.R., Clark, S.A., et al. (2005). Akt/protein kinase B activation by adenovirus vectors contributes to NFkappaB-dependent CXCL10 expression. J. Virol. 79, 14507-14515. (Pubitemid 41636249)
97. Lockett, L.J., and Both, G.W. (2002). Complementation of a defective human adenovirus by an otherwise incompatible ovine adenovirus recombinant carrying a functional E1A gene. Virology 294, 333-341. (Pubitemid 34920532)
98. Logunov, D.Y., Ilyinskaya, G.V., Cherenova, L.V., et al. (2004). Restoration of p53 tumor-suppressor activity in human tumor cells in vitro and in their xenografts in vivo by recombinant avian adenovirus CELO-p53. Gene Ther. 11, 79-84. (Pubitemid 38111391)
99. Löser, P., Hillgenberg, M., Arnold, W., et al. (2000). Ovine adenovirus vectors mediate efficient gene transfer to skeletal muscle. Gene Ther. 7, 1491-1498.
100. Löser, P., Hofmann, C., Both, G.W., et al. (2003). Construction, rescue, and characterization of vectors derived from ovine atadenovirus. J. Virol. 77, 11941-11951. (Pubitemid 37339848)
101. Lukashev, A.N., Ivanova, O.E., Eremeeva, T.P., and Iggo, R.D. (2008). Evidence of frequent recombination among human adenoviruses. J. Gen. Virol. 89, 380-388. (Pubitemid 351622435)
102. Mack, C.A., Song, W.R., Carpenter, H., et al. (1997). Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum. Gene Ther. 8, 99-109. (Pubitemid 27075347)
103. Maione, D., Della Rocca, C., Giannetti, P., et al. (2001). An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus. Proc. Natl. Acad. Sci. USA 98, 5986-5991. (Pubitemid 32488180)
104. Martiniello-Wilks, R., Dane, A., Voeks, D.J., et al. (2004). Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease. J. Gene Med. 6, 43-54. (Pubitemid 40228002)
105. Mastrangeli, A., Harvey, B.G., Yao, J., et al. (1996). "Seroswitch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Hum. Gene Ther. 7, 79-87.
106. McVey, D., Zuber, M., Ettyreddy, D., et al. (2010). Characterization of human adenovirus 35 and derivation of complex vectors. Virol. J. 7, 276.
107. Michou, A.I., Lehrmann, H., Saltik, M., and Cotten, M. (1999). Mutational analysis of the avian adenovirus CELO, which provides a basis for gene delivery vectors. J. Virol. 73, 1399-1410. (Pubitemid 29036795)
108. Mittal, S.K., Prevec, L., Graham, F.L., and Babiuk, L.A. (1995). Development of a bovine adenovirus type 3-based expression vector. J. Gen. Virol. 76 (Pt 1), 93-102.
109. Mok, H., Palmer, D.J., Ng, P., and Barry, M.A. (2005). Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol. Ther. 11, 66-79. (Pubitemid 40012000)
110. Morrison, J., Briggs, S.S., Green, N., et al. (2008). Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor. Mol. Ther. 16, 244-251. (Pubitemid 351168032)
111. Morrison, J., Briggs, S.S., Green, N.K., et al. (2009). Cetuximab retargeting of adenovirus via the epidermal growth factor receptor for treatment of intraperitoneal ovarian cancer. Hum. Gene Ther. 20, 239-251.
112. Muruve, D.A., Pétrilli, V., Zaiss, A.K., et al. (2008). The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 452, 103-107. (Pubitemid 351355095)
113. Myhre, S., Henning, P., Granio, O., et al. (2007). Decreased immune reactivity towards a knobless, affibody-targeted adenovirus type 5 vector. Gene Ther. 14, 376-381. (Pubitemid 46231931)
114. Nan, X., Peng, B., Hahn, T.W., et al. (2003). Development of an Ad7 cosmid system and generation of an Ad7-deltaE1deltaE3HIV(MN) env/rev recombinant virus. Gene Ther. 10, 326-336. (Pubitemid 36305601)
115. Nguyen, T., Nery, J., Joseph, S., et al. (1999). Mouse adenovirus (MAV-1) expression in primary human endothelial cells and generation of a full-length infectious plasmid. Gene Ther. 6, 1291-1297. (Pubitemid 29359023)
116. Ni, S., Bernt, K., Gaggar, A., et al. (2005). Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons. Hum. Gene Ther. 16, 664-677. (Pubitemid 40864267)
117. Nicol, C.G., Graham, D., Miller, W.H., et al. (2004). Effect of adenovirus serotype 5 fiber and penton modifications on in vivo tropism in rats. Mol. Ther. 10, 344-354. (Pubitemid 39117879)
118. Ojkic, D., and Nagy, E. (2001). The long repeat region is dispensable for fowl adenovirus replication in vitro. Virology 283, 197-206. (Pubitemid 32881167)
119. Ojkic, D., and Nagy, E. (2003). Antibody response and virus tissue distribution in chickens inoculated with wild-type and recombinant fowl adenoviruses. Vaccine 22, 42-48. (Pubitemid 37357151)
120. Olive, M., Eisenlohr, L., Flomenberg, N., et al. (2002). The adenovirus capsid protein hexon contains a highly conserved human CD4 + T-cell epitope. Hum. Gene Ther. 13, 1167-1178. (Pubitemid 34746697)
121. Ord, E., Shirley, R., McClure, J., et al. (2013). Combined antiapoptotic and antioxidant approach to acute neuroprotection for stroke in hypertensive rats. J. Cereb. Blood Flow Metab. 33, 1215-1224.
122. Ostapchuk, P., and Hearing, P. (2001). Pseudopackaging of adenovirus type 5 genomes into capsids containing the hexon proteins of adenovirus serotypes B, D, or E. J. Virol. 75, 45-51.
123. Pahl, J.H., Verhoeven, D.H., Kwappenberg, K.M., et al. (2012). Adenovirus type 35, but not type 5, stimulates NK cell activation via plasmacytoid dendritic cells and TLR9 signaling. Mol. Immunol. 51, 91-100.
124. Parker, A.L., Fisher, K.D., Oupicky, D., et al. (2005). Enhanced gene transfer activity of peptide-targeted gene-delivery vectors. J. Drug Target. 13, 39-51. (Pubitemid 40309460)
125. Parker, A.L., Waddington, S.N., Nicol, C.G., et al. (2006). Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood 108, 2554-2561.
126. Parker, A.L., Waddington, S.N., Buckley, S.M., et al. (2009). Effect of neutralizing sera on factor x-mediated adenovirus serotype 5 gene transfer. J. Virol. 83, 479-483.
127. Parks, R., Evelegh, C., and Graham, F. (1999). Use of helperdependent adenoviral vectors of alternative serotypes permits repeat vector administration. Gene Ther. 6, 1565-1573. (Pubitemid 29465515)
128. Perreau, M., and Kremer, E.J. (2006). The conundrum between immunological memory to adenovirus and their use as vectors in clinical gene therapy. Mol. Biotechnol. 34, 247-256. (Pubitemid 46030398)
129. Perreau, M., Welles, H.C., Pellaton, C., et al. (2012). The number of Toll-like receptor 9-agonist motifs in the adenovirus genome correlates with induction of dendritic cell maturation by adenovirus immune complexes. J. Virol. 86, 6279-6285.
130. Pichla-Gollon, S.L., Drinker, M., Zhou, X., et al. (2007). Structure-based identification of a major neutralizing site in an adenovirus hexon. J. Virol. 81, 1680-1689. (Pubitemid 46214443)
131. Piersanti, S., Astrologo, L., Licursi, V., et al. (2013). Differentiated neuroprogenitor cells incubated with human or canine adenovirus, or lentiviral vectors have distinct transcriptome profiles. Plos One 8, e69808.
132. Purkayastha, A., Ditty, S.E., Su, J., et al. (2005a). Genomic and bioinformatics analysis of HAdV-4, a human adenovirus causing acute respiratory disease: implications for gene therapy and vaccine vector development. J. Virol. 79, 2559-2572. (Pubitemid 40204610)
133. Purkayastha, A., Su, J., Carlisle, S., et al. (2005b). Genomic and bioinformatics analysis of HAdV-7, a human adenovirus of species B1 that causes acute respiratory disease: implications for vector development in human gene therapy. Virology 332, 114-129. (Pubitemid 40127234)
134. Quinn, K.M., Da Costa, A., Yamamoto, A., et al. (2013). Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8 + T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization. J. Immunol. 190, 2720-2735.
135. Raman, S., Hsu, T.H., Ashley, S.L., and Spindler, K.R. (2009). Usage of integrin and heparan sulfate as receptors for mouse adenovirus type 1. J. Virol. 83, 2831-2838.
136. Raper, S.E., Chirmule, N., Lee, F.S., et al. (2003). Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. 80, 148-158. (Pubitemid 37272241)
137. Rasmussen, U.B., Benchaibi, M., Meyer, V., et al. (1999). Novel human gene transfer vectors: evaluation of wild-type and recombinant animal adenoviruses in human-derived cells. Hum. Gene Ther. 10, 2587-2599.
138. Reddy, P.S., Idamakanti, N., Babiuk, L.A., et al. (1999a). Porcine adenovirus-3 as a helper-dependent expression vector. J. Gen. Virol. 80 (Pt 11), 2909-2916. (Pubitemid 29504662)
139. Reddy, P.S., Idamakanti, N., Hyun, B.H., et al. (1999b). Development of porcine adenovirus-3 as an expression vector. J. Gen. Virol. 80 (Pt 3), 563-570. (Pubitemid 29101209)
140. Roberts, D.M., Nanda, A., Havenga, M.J., et al. (2006). Hexonchimaeric adenovirus serotype 5 vectors circumvent preexisting anti-vector immunity. Nature 441, 239-243.
141. Robinson, M., Li, B., Ge, Y., et al. (2009). Novel immunocompetent murine tumor model for evaluation of conditionally replication-competent (oncolytic) murine adenoviral vectors. J. Virol. 83, 3450-3462.
142. Rogée, S., Grellier, E., Bernard, C., et al. (2010). Influence of chimeric human-bovine fibers on adenoviral uptake by liver cells and the antiviral immune response. Gene Ther. 17, 880-891.
143. Rogozhin, V.N., Logunov, D.Y., Shchebliakov, D.V., et al. (2011). An efficient method for the delivery of the interleukin-2 gene to human hematopoietic cells using the fiber-modified recombinant adenovirus. Acta Nat. 3, 100-106.
144. Romanczuk, H., Galer, C.E., Zabner, J., et al. (1999). Modification of an adenoviral vector with biologically selected peptides: a novel strategy for gene delivery to cells of choice. Hum. Gene Ther. 10, 2615-2626.
145. Rowe, W.P., Huebner, R.J., Gilmore, L.K., et al. (1953). Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc. Soc. Exp. Biol. Med. 84, 570-573.
146. Roy, S., Shirley, P.S., McClelland, A., and Kaleko, M. (1998). Circumvention of immunity to the adenovirus major coat protein hexon. J. Virol. 72, 6875-6879. (Pubitemid 28324008)
147. Roy, S., Gao, G.P., Lu, Y., et al. (2004). Characterization of a family of chimpanzee adenoviruses and development of molecular clones for gene transfer vectors. Hum. Gene Ther. 15, 519-530. (Pubitemid 38639622)
148. Roy, S., Clawson, D.S., Calcedo, R., et al. (2005). Use of chimeric adenoviral vectors to assess capsid neutralization determinants. Virology 333, 207-214. (Pubitemid 40250106)
149. Roy, S., Clawson, D.S., Adam, V.S., et al. (2011a). Construction of gene transfer vectors based on simian adenovirus 7. J. Gen. Virol. 92, 1749-1753.
150. Roy, S., Medina-Jaszek, A., Wilson, M.J., et al. (2011b). Creation of a panel of vectors based on ape adenovirus isolates. J. Gene Med. 13, 17-25.
151. Rux, J.J., and Burnett, R.M. (2000). Type-specific epitope locations revealed by X-ray crystallographic study of adenovirus type 5 hexon. Mol. Ther. 1, 18-30.
152. Sakurai, F. (2008). Development of a replication-incompetent adenovirus vector derived from subgroup B adenovirus serotype 35. Yakuga. Zasshi 128, 1751-1761.
153. Sakurai, F., Mizuguchi, H., and Hayakawa, T. (2003). Efficient gene transfer into human CD34 + cells by an adenovirus type 35 vector. Gene Ther. 10, 1041-1048. (Pubitemid 36722495)
154. Sakurai, F., Nakamura, S.I., Akitomo, K., et al. (2009). Adenovirus serotype 35 vector-mediated transduction following direct administration into organs of nonhuman primates. Gene Ther. 16, 297-302.
155. Schoehn, G., El Bakkouri, M., Fabry, C.M., et al. (2008). Three-dimensional structure of canine adenovirus serotype 2 capsid. J. Virol. 82, 3192-3203. (Pubitemid 351429900)
156. Schoggins, J.W., Nociari, M., Philpott, N., and Falck-Pedersen, E. (2005). Influence of fiber detargeting on adenovirusmediated innate and adaptive immune activation. J. Virol. 79, 11627-11637. (Pubitemid 41279281)
157. Schumacher, L., Ribas, A., Dissette, V.B., et al. (2004). Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses. J. Immunother. 27, 191-200. (Pubitemid 39118083)
158. Segura, M.M., Puig, M., Monfar, M., and Chillón, M. (2012). Chromatography purification of canine adenoviral vectors. Hum. Gene Ther. Methods 23, 182-197.
159. Seiradake, E., Henaff, D., Wodrich, H., et al. (2009). The cell adhesion molecule "CAR" and sialic acid on human erythrocytes influence adenovirus in vivo biodistribution. PLoS Pathog. 5, e1000277.
160. Seshidhar Reddy, P., Ganesh, S., Limbach, M.P., et al. (2003). Development of adenovirus serotype 35 as a gene transfer vector. Virology 311, 384-393. (Pubitemid 36808779)
161. Sharma, A., Bangari, D.S., Tandon, M., et al. (2009a). Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model. Virology 386, 44-54.
162. Sharma, A., Li, X., Bangari, D.S., and Mittal, S.K. (2009b). Adenovirus receptors and their implications in gene delivery. Virus Res. 143, 184-194.
163. Sharma, A., Bangari, D.S., Vemula, S.V., and Mittal, S.K. (2011). Persistence and the state of bovine and porcine adenoviral vector genomes in human and nonhuman cell lines. Virus Res. 161, 181-187.
164. Shashkova, E.V., Cherenova, L.V., Kazansky, D.B., and Doronin, K. (2005). Avian adenovirus vector CELO-TK displays anticancer activity in human cancer cells and suppresses established murine melanoma tumors. Cancer Gene Ther. 12, 617-626. (Pubitemid 40967222)
165. Shayakhmetov, D.M., Papayannopoulou, T., Stamatoyannopoulos, G., and Lieber, A. (2000). Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J. Virol. 74, 2567-2583. (Pubitemid 30117566)
166. Shayakhmetov, D.M., Gaggar, A., Ni, S., et al. (2005). Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J. Virol. 79, 7478-7491. (Pubitemid 40756784)
167. Sheppard, M., Werner, W., Tsatas, E., et al. (1998). Fowl adenovirus recombinant expressing VP2 of infectious bursal disease virus induces protective immunity against bursal disease. Arch. Virol. 143, 915-930. (Pubitemid 28257906)
168. Shimizu, T., Ichihara, M., Yoshioka, Y., et al. (2012). Intravenous administration of polyethylene glycol-coated (PEGylated) proteins and PEGylated adenovirus elicits an anti-PEG immunoglobulin M response. Biol. Pharm. Bull. 35, 1336-1342.
169. Shiratsuchi, T., Rai, U., Krause, A., et al. (2010). Replacing adenoviral vector HVR1 with a malaria B cell epitope improves immunogenicity and circumvents preexisting immunity to adenovirus in mice. J. Clin. Invest. 120, 3688-3701.
170. Shiver, J.W., and Emini, E.A. (2004). Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu. Rev. Med. 55, 355-372. (Pubitemid 38316732)
171. Shmarov, M.M., Cherenova, L.V., Shashkova, E.V., et al. (2002). Eukaryotic vectors of Celo avian adenovirus genome, carrying GFP and human IL-2 genes. Mol. Gen. Mikrobiol. Virusol. 2, 30-35.
172. Skog, J., Edlund, K., Bergenheim, A.T., and Wadell, G. (2007). Adenoviruses 16 and CV23 efficiently transduce human lowpassage brain tumor and cancer stem cells. Mol. Ther. 15, 2140-2145. (Pubitemid 350148930)
173. Soudais, C., Boutin, S., Hong, S.S., et al. (2000). Canine adenovirus type 2 attachment and internalization: coxsackievirusadenovirus receptor, alternative receptors, and an RGDindependent pathway. J. Virol. 74, 10639-10649.
174. Soudais, C., Laplace-Builhe, C., Kissa, K., and Kremer, E.J. (2001). Preferential transduction of neurons by canine adenovirus vectors and their efficient retrograde transport in vivo. FASEB J. 15, 2283-2285.
175. Stephen, S.L., Montini, E., Sivanandam, V.G., et al. (2010). Chromosomal integration of adenoviral vector DNA in vivo. J. Virol. 84, 9987-9994.
176. Stevenson, M., Boos, E., Herbert, C., et al. (2006). Chick embryo lethal orphan virus can be polymer-coated and retargeted to infect mammalian cells. Gene Ther. 13, 356-368. (Pubitemid 43223105)
177. Stevenson, M., Hale, A.B., Hale, S.J., et al. (2007). Incorporation of a laminin-derived peptide (SIKVAV) on polymer-modified adenovirus permits tumor-specific targeting via alpha6-integrins. Cancer Gene Ther. 14, 335-345. (Pubitemid 46425781)
178. Stone, D., Ni, S., Li, Z.Y., et al. (2005). Development and assessment of human adenovirus type 11 as a gene transfer vector. J. Virol. 79, 5090-5104. (Pubitemid 40464259)
179. Sullivan, N.J., Geisbert, T.W., Geisbert, J.B., et al. (2003). Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424, 681-684. (Pubitemid 36987993)
180. Sumida, S.M., Truitt, D.M., Lemckert, A.A., et al. (2005). Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J. Immunol. 174, 7179-7185. (Pubitemid 40705685)
181. Tamanini, A., Nicolis, E., Bonizzato, A., et al. (2006). Interaction of adenovirus type 5 fiber with the coxsackievirus and adenovirus receptor activates inflammatory response in human respiratory cells. J. Virol. 80, 11241-11254. (Pubitemid 44706564)
182. Tan, P.K., Michou, A.I., Bergelson, J.M., and Cotten, M. (2001). Defining CAR as a cellular receptor for the avian adenovirus CELO using a genetic analysis of the two viral fibre proteins. J. Gen. Virol. 82, 1465-1472. (Pubitemid 32519778)
183. Tandon, M., Sharma, A., Vemula, S.V., et al. (2012). Sequential administration of bovine and human adenovirus vectors to overcome vector immunity in an immunocompetent mouse model of breast cancer. Virus Res. 163, 202-211.
184. Tang, J., Olive, M., Pulmanausahakul, R., et al. (2006). Human CD8 + cytotoxic T cell responses to adenovirus capsid proteins. Virology 350, 312-322. (Pubitemid 43928100)
185. Tang, R., Li, K., Wilson, M., et al. (2012). Potent antietumor immunity in mice induced by vaccination with an ovine atadenovirus vector. J. Immunother. 35, 32-41.
186. Tarassishin, L., Szawlowski, P., Kidd, A.H., and Russell, W.C. (2000). An epitope on the adenovirus fibre tail is common to all human subgroups. Arch. Virol. 145, 805-811. (Pubitemid 30301843)
187. Tian, X., Su, X., Li, H., et al. (2011). Construction and characterization of human adenovirus serotype 3 packaged by serotype 7 hexon. Virus Res. 160, 214-220.
188. Tomko, R.P., Xu, R., and Philipson, L. (1997). HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc. Natl. Acad. Sci. USA 94, 3352-3356. (Pubitemid 27157315)
189. Tripathy, S.K., Black, H.B., Goldwasser, E., and Leiden, J.M. (1996). Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replicationdefective adenovirus vectors. Nat. Med. 2, 545-550.
190. Tuboly, T., Nagy, E., and Derbyshire, J.B. (1993). Potential viral vectors for the stimulation of mucosal antibody responses against enteric viral antigens in pigs. Res. Vet. Sci. 54, 345-350. (Pubitemid 23171884)
191. Tutykhina, I.L., Shmarov, M.M., Logunov, D.I., et al. (2008). Construction of the vector based on the CELO avian adenovirus genome providing enhanced expression of secreted alkaline phosphatase gene in a non-permissive system in vitro and in vivo. Mol. Gen. Mikrobiol. Virusol. 4, 26-30.
192. Ulasov, I.V., Rivera, A.A., Han, Y., et al. (2007). Targeting adenovirus to CD80 and CD86 receptors increases gene transfer efficiency to malignant glioma cells. J. Neurosurg. 107, 617-627. (Pubitemid 47451047)
193. Varnavski, A.N., Schlienger, K., Bergelson, J.M., et al. (2003). Efficient transduction of human monocyte-derived dendritic cells by chimpanzee-derived adenoviral vector. Hum. Gene Ther. 14, 533-544. (Pubitemid 36438938)
194. Vellinga, J., Van der Heijdt, S., and Hoeben, R.C. (2005). The adenovirus capsid: major progress in minor proteins. J. Gen. Virol. 86, 1581-1588. (Pubitemid 40774764)
195. Voeks, D., Martiniello-Wilks, R., Madden, V., et al. (2002). Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models. Gene Ther. 9, 759-768. (Pubitemid 34679303)
196. Vogels, R., Zuijdgeest, D., van Rijnsoever, R., et al. (2003). Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J. Virol. 77, 8263-8271. (Pubitemid 36871454)
197. Volk, A.L., Rivera, A.A., Kanerva, A., et al. (2003). Enhanced adenovirus infection of melanoma cells by fiber-modification: incorporation of RGD peptide or Ad5/3 chimerism. Cancer Biol. Ther. 2, 511-515.
198. Vrati, S., Macavoy, E.S., Xu, Z.Z., et al. (1996). Construction and transfection of ovine adenovirus genomic clones to rescue modified viruses. Virology 220, 200-203. (Pubitemid 26201676)
199. Vujanovic, L., Whiteside, T.L., Potter, D.M., et al. (2009). Regulation of antigen presentation machinery in human dendritic cells by recombinant adenovirus. Cancer Immunol. Immunother. 58, 121-133.
200. Walsh, M.P., Seto, J., Liu, E.B., et al. (2011). Computational analysis of two species C human adenoviruses provides evidence of a novel virus. J. Clin. Microbiol. 49, 3482-3490.
201. Wang, I.J., Jhuang, M.C., Chen, Y.H., et al. (2010). Chitosan modification of adenovirus to modify transfection efficiency in bovine corneal epithelial cells. PLoS One 5, e12085.
202. Wang, C.H., Chan, L.W., Johnson, R.N., et al. (2011a). The transduction of Coxsackie and Adenovirus Receptor-negative cells and protection against neutralizing antibodies by HPMA-co-oligolysine copolymer-coated adenovirus. Biomaterials 32, 9536-9545.
203. Wang, D.Y., Liu, S.H., Li, X., et al. (2011b). Study on construction of chimeric adenovirus vector Ad5/11 carrying human eGFP and endostatin-K5 and its experimental investigation in vitro. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 27, 143-145.
204. Wohlfart, C. (1988). Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms. J. Virol. 62, 2321-2328.
205. Wu, Q., and Tikoo, S.K. (2004). Altered tropism of recombinant bovine adenovirus type-3 expressing chimeric fiber. Virus Res. 99, 9-15. (Pubitemid 37542485)
206. Wu, H., Dmitriev, I., Kashentseva, E., et al. (2002). Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon. J. Virol. 76, 12775-12782. (Pubitemid 35386961)
207. Xiang, Z., Gao, G., Reyes-Sandoval, A., et al. (2002). Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J. Virol. 76, 2667-2675. (Pubitemid 34184852)
208. Xiang, Z., Li, Y., Cun, A., et al. (2006). Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg. Infect. Dis. 12, 1596-1599. (Pubitemid 44570909)
209. Xu, Z.Z., and Both, G.W. (1998). Altered tropism of an ovine adenovirus carrying the fiber protein cell binding domain of human adenovirus type 5. Virology 248, 156-163. (Pubitemid 28393939)
210. Xu, Z.Z., Hyatt, A., Boyle, D.B., and Both, G.W. (1997). Construction of ovine adenovirus recombinants by gene insertion or deletion of related terminal region sequences. Virology 230, 62-71. (Pubitemid 27243522)
211. Xu, Z.Z., Nevels, M., MacAvoy, E.S., et al. (2000). An ovine adenovirus vector lacks transforming ability in cells that are transformed by AD5 E1A/B sequences. Virology 270, 162-172. (Pubitemid 30256548)
212. Xu, Z., Tian, J., Smith, J.S., and Byrnes, A.P. (2008). Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement. J. Virol. 82, 11705-11713.
213. Xu, Z., Qiu, Q., Tian, J., et al. (2013). Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement. Nat. Med. 19, 452-457.
214. Yamaguchi, T., Kawabata, K., Koizumi, N., et al. (2007). Role of MyD88 and TLR9 in the innate immune response elicited by serotype 5 adenoviral vectors. Hum. Gene Ther. 18, 753-762. (Pubitemid 47378072)
215. Yao, X., Yoshioka, Y., Morishige, T., et al. (2010). Adenovirus vector covalently conjugated to polyethylene glycol with a cancer-specific promoter suppresses the tumor growth through systemic administration. Biol. Pharm. Bull. 33, 1073-1076.
216. Ying, B., Smith, K., and Spindler, K.R. (1998). Mouse adenovirus type 1 early region 1A is dispensable for growth in cultured fibroblasts. J. Virol. 72, 6325-6331. (Pubitemid 28323942)
217. Youil, R., Toner, T.J., Su, Q., et al. (2002). Hexon gene switch strategy for the generation of chimeric recombinant adenovirus. Hum. Gene Ther. 13, 311-320. (Pubitemid 34164114)
218. Yu, B., Dong, J., Wang, C., et al. (2013). Characteristics of neutralizing antibodies to adenovirus capsid proteins in human and animal sera. Virology 437, 118-123.
219. Zaiss, A.K., Vilaysane, A., Cotter, M.J., et al. (2009). Antiviral antibodies target adenovirus to phagolysosomes and amplify the innate immune response. J. Immunol. 182, 7058-7068.
220. Zakhartchouk, A.N., Wu, Q., and Tikoo, S.K. (2007). Construction of capsid-modified recombinant bovine adenovirus type 3. Methods Mol. Med. 130, 91-106.
221. Zeng, Q., Han, J., Zhao, D., et al. (2012). Protection of adenovirus from neutralizing antibody by cationic PEG derivative ionically linked to adenovirus. Int. J. Nanomed. 7, 985-997.
222. Zhang, S., Huang, W., Zhou, X., et al. (2013a). Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults. J. Med. Virol. 85, 1077-1084.
223. Zhang, W.F., Wu, F.L., Shao, H.W., et al. (2013b). Chimeric adenoviral vector Ad5F35L containing the Ad5 natural longshaft exhibits efficient gene transfer into human T lymphocytes. J. Virol. Methods 194, 52-59.
224. Zhu, J., Huang, X., and Yang, Y. (2007). Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and-independent pathways. J. Virol. 81, 3170-3180. (Pubitemid 46456626)
225. Zhu, J., Huang, X., and Yang, Y. (2008). A critical role for type I IFN-dependent NK cell activation in innate immune elimination of adenoviral vectors in vivo. Mol. Ther. 16, 1300-1307. (Pubitemid 351866062)